Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer
F Nurhayati, Y Anggriani, E Syahruddin… - Journal of Applied …, 2021 - japsonline.com
Tyrosine kinase inhibitors (TKIs; eg, erlotinib, gefitinib, and afatinib) are the first-line therapy
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …
Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer
F Nurhayati, Y Anggriani, E Syahruddin… - Journal of Applied …, 2021 - scholar.ui.ac.id
Tyrosine kinase inhibitors (TKIs; eg, erlotinib, gefitinib, and afatinib) are the first-line therapy
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …
[PDF][PDF] Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer
F Nurhayati, Y Anggriani, E Syahruddin… - Journal of Applied …, 2021 - researchgate.net
Tyrosine kinase inhibitors (TKIs; eg, erlotinib, gefitinib, and afatinib) are the first-line therapy
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …
[PDF][PDF] Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer
F Nurhayati, Y Anggriani, E Syahruddin… - Journal of Applied …, 2021 - japsonline.com
Tyrosine kinase inhibitors (TKIs; eg, erlotinib, gefitinib, and afatinib) are the first-line therapy
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …
[PDF][PDF] Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer
F Nurhayati, Y Anggriani, E Syahruddin… - Journal of Applied …, 2021 - japsonline.com
Tyrosine kinase inhibitors (TKIs; eg, erlotinib, gefitinib, and afatinib) are the first-line therapy
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …